Connor, Clark & Lunn Investment Management (CC&L)’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $421K | Buy |
|
|||||
|
2024
Q2 | – | Sell |
|
|||||
|
2024
Q1 | $115K | Buy |
|
|||||
|
2023
Q4 | $61.6K | Buy |
|
|||||
|
2023
Q3 | $47.3K | Sell |
|
|||||
|
2023
Q2 | $67.1K | Sell |
|
|||||
|
2023
Q1 | $729K | Sell |
|
|||||
|
2022
Q4 | $1.47M | Buy |
|
|||||
|
2022
Q3 | $849K | Buy |
|
|||||
|
2022
Q2 | $207K | Buy |
|
|||||
|
2019
Q3 | – | Sell |
|
|||||
|
2019
Q2 | $346K | Sell |
|
|||||
|
2019
Q1 | $765K | Buy |
|
|||||
|
2016
Q2 | – | Sell |
|
|||||
|
2016
Q1 | $244K | Sell |
|
|||||
|
2015
Q4 | $545K | Buy |
|
|||||
|
2015
Q3 | $422K | Sell |
|
|||||
|
2015
Q2 | $1.24M | Buy |
|
|||||
|
2015
Q1 | $1.35M | Buy |
|
|||||
|
2014
Q4 | $412K | Buy |
|